Cargando…

Neutrophil–lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas

OBJECTIVE: Distinguishing recurrence and pseudoprogression is a major challenge in the clinical practice of treatment for high-grade gliomas (HGGs). The neutrophil–lymphocyte ratio (NLR) has been reported to be closely related to survival in HGGs. We aimed to assess the predictive value of NLR in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yong, Ding, Haixia, Wu, Qiuji, Li, Zhiqiang, Li, Huan, Li, Sirui, Xie, Conghua, Zhong, Yahua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611708/
https://www.ncbi.nlm.nih.gov/pubmed/31303796
http://dx.doi.org/10.2147/CMAR.S202546
_version_ 1783432746680451072
author Huang, Yong
Ding, Haixia
Wu, Qiuji
Li, Zhiqiang
Li, Huan
Li, Sirui
Xie, Conghua
Zhong, Yahua
author_facet Huang, Yong
Ding, Haixia
Wu, Qiuji
Li, Zhiqiang
Li, Huan
Li, Sirui
Xie, Conghua
Zhong, Yahua
author_sort Huang, Yong
collection PubMed
description OBJECTIVE: Distinguishing recurrence and pseudoprogression is a major challenge in the clinical practice of treatment for high-grade gliomas (HGGs). The neutrophil–lymphocyte ratio (NLR) has been reported to be closely related to survival in HGGs. We aimed to assess the predictive value of NLR in the differential diagnosis of recurrence and pseudoprogression. MATERIALS AND METHODS: A total of 135 patients with histologically confirmed HGGs were studied. All patients underwent focal radiotherapy and concomitant temozolomide (TMZ), followed by 6 cycles of TMZ if MRI showed no progressive enlargement of contrast-enhancing lesions. MRI evaluation was taken 4 weeks after concurrent chemoradiotherapy and then every 2 months later. NLR was calculated at 4 time points of preoperation, before concurrent RT-TMZ (pretreatment), 4 weeks following completion of RT-TMZ, and MRI showed lesion enlarged or treatment completed. RESULTS: In 135 patients, 47 (34.8%) were found to be pseudoprogression (PsPD), and 28 (20.7%) were early disease progression (ePD). The mean pretreatment and post-treatment NLR were 4.2±2.1 and 5.1±3.5, respectively. The median overall survival in the PsPD group (25.2 months) was significantly longer than in the ePD (15.4 months) and no progression group (nPD) (21.6 months) (p<0.001). Overall survival was significantly shorter in the baseline NLR≥4 cohort compared with NLR<4 (p=0.03), but no significant difference was found between PsPD and ePD (p=0.197). Patients with decreased NLR showed significantly longer survival than no decreased group (p<0.001), and decreased NLR was found to be a significant difference between PsPD and ePD (p=0.022). Univariate and multivariate logistic regression analyses suggested that decreased NLR was an independent prognosis factor (p=0.031). CONCLUSION: Decreased NLR is an independent prognostic factor and is useful for distinguishing between recurrence and pseudoprogression in HGGs.
format Online
Article
Text
id pubmed-6611708
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66117082019-07-12 Neutrophil–lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas Huang, Yong Ding, Haixia Wu, Qiuji Li, Zhiqiang Li, Huan Li, Sirui Xie, Conghua Zhong, Yahua Cancer Manag Res Original Research OBJECTIVE: Distinguishing recurrence and pseudoprogression is a major challenge in the clinical practice of treatment for high-grade gliomas (HGGs). The neutrophil–lymphocyte ratio (NLR) has been reported to be closely related to survival in HGGs. We aimed to assess the predictive value of NLR in the differential diagnosis of recurrence and pseudoprogression. MATERIALS AND METHODS: A total of 135 patients with histologically confirmed HGGs were studied. All patients underwent focal radiotherapy and concomitant temozolomide (TMZ), followed by 6 cycles of TMZ if MRI showed no progressive enlargement of contrast-enhancing lesions. MRI evaluation was taken 4 weeks after concurrent chemoradiotherapy and then every 2 months later. NLR was calculated at 4 time points of preoperation, before concurrent RT-TMZ (pretreatment), 4 weeks following completion of RT-TMZ, and MRI showed lesion enlarged or treatment completed. RESULTS: In 135 patients, 47 (34.8%) were found to be pseudoprogression (PsPD), and 28 (20.7%) were early disease progression (ePD). The mean pretreatment and post-treatment NLR were 4.2±2.1 and 5.1±3.5, respectively. The median overall survival in the PsPD group (25.2 months) was significantly longer than in the ePD (15.4 months) and no progression group (nPD) (21.6 months) (p<0.001). Overall survival was significantly shorter in the baseline NLR≥4 cohort compared with NLR<4 (p=0.03), but no significant difference was found between PsPD and ePD (p=0.197). Patients with decreased NLR showed significantly longer survival than no decreased group (p<0.001), and decreased NLR was found to be a significant difference between PsPD and ePD (p=0.022). Univariate and multivariate logistic regression analyses suggested that decreased NLR was an independent prognosis factor (p=0.031). CONCLUSION: Decreased NLR is an independent prognostic factor and is useful for distinguishing between recurrence and pseudoprogression in HGGs. Dove 2019-07-01 /pmc/articles/PMC6611708/ /pubmed/31303796 http://dx.doi.org/10.2147/CMAR.S202546 Text en © 2019 Huang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Huang, Yong
Ding, Haixia
Wu, Qiuji
Li, Zhiqiang
Li, Huan
Li, Sirui
Xie, Conghua
Zhong, Yahua
Neutrophil–lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas
title Neutrophil–lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas
title_full Neutrophil–lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas
title_fullStr Neutrophil–lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas
title_full_unstemmed Neutrophil–lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas
title_short Neutrophil–lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas
title_sort neutrophil–lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611708/
https://www.ncbi.nlm.nih.gov/pubmed/31303796
http://dx.doi.org/10.2147/CMAR.S202546
work_keys_str_mv AT huangyong neutrophillymphocyteratiodynamicsareusefulfordistinguishingbetweenrecurrenceandpseudoprogressioninhighgradegliomas
AT dinghaixia neutrophillymphocyteratiodynamicsareusefulfordistinguishingbetweenrecurrenceandpseudoprogressioninhighgradegliomas
AT wuqiuji neutrophillymphocyteratiodynamicsareusefulfordistinguishingbetweenrecurrenceandpseudoprogressioninhighgradegliomas
AT lizhiqiang neutrophillymphocyteratiodynamicsareusefulfordistinguishingbetweenrecurrenceandpseudoprogressioninhighgradegliomas
AT lihuan neutrophillymphocyteratiodynamicsareusefulfordistinguishingbetweenrecurrenceandpseudoprogressioninhighgradegliomas
AT lisirui neutrophillymphocyteratiodynamicsareusefulfordistinguishingbetweenrecurrenceandpseudoprogressioninhighgradegliomas
AT xieconghua neutrophillymphocyteratiodynamicsareusefulfordistinguishingbetweenrecurrenceandpseudoprogressioninhighgradegliomas
AT zhongyahua neutrophillymphocyteratiodynamicsareusefulfordistinguishingbetweenrecurrenceandpseudoprogressioninhighgradegliomas